SCHEMBL8397164

SCHEMBL8397164

CCOc1cc(-c2cc(OCC)cc(C(C)(C)C)c2O)c(O)c(C(C)(C)C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.50
CA1 P00915 2/20 0.50
PTGS1 P23219 2/20 0.45
PTGS2 P35354 1/20 0.45
MAPT P10636 2/20 0.41
ALOX15 P16050 2/20 0.41
HPN P05981 1/20 0.41
SIRT5 Q9NXA8 1/20 0.41
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
POLB P06746 1/20 0.41
TYR P14679 1/20 0.41
HSPA5 P11021 2/20 0.40
HMGCR P04035 2/20 0.39
NR1I2 O75469 1/20 0.39
CYP2C9 P11712 5/20 0.39
CYP2C19 P33261 5/20 0.39
HIF1A Q16665 4/20 0.39
TSHR P16473 4/20 0.39
CYP1A2 P05177 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL448549 0.90 CA2 (0.61) CA2CA1PTGS1PTGS2MAPT
SCHEMBL15064757 0.86 PTGS1 (0.48) CA2CA1PTGS1PTGS2MAPT
SCHEMBL15064805 0.84 CA2 (0.46) CA2CA1PTGS1MAPTALOX15
SCHEMBL10951644 0.84 CYP2C9 (0.53) CA2CA1PTGS1PTGS2MAPT
SCHEMBL10613533 0.82 HSPA5 (0.61) CA2CA1PTGS1PTGS2MAPT
SCHEMBL15064910 0.81 CA2 (0.46) CA2CA1PTGS1PTGS2MAPT
SCHEMBL29602570 0.79 CA2 (0.80) CA2CA1PTGS1PTGS2MAPT
SCHEMBL240515 0.79 CA2 (0.80) CA2CA1PTGS1PTGS2MAPT
SCHEMBL11778040 0.78 GLRA3 (0.46) CA2CA1PTGS1PTGS2MAPT
SCHEMBL2288807 0.78 CA1 (0.41) CA2CA1PTGS1PTGS2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0509740-B1 Heat-developable photosensitive material and image forming method making use of the heat-developable photosensitive material CANON KK (JP) 1996-06-26 EP claimed
EP-2797938-B1 METHOD FOR PRODUCING 6-CHLORODIBENZO [D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2016-06-01 EP disclosed
EP-2797938-A1 METHOD FOR PRODUCING 6-CHLORODIBENZO [D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2014-11-05 EP disclosed
US-8841474-B2 Process for preparing 6-chlorodibenzo[D,F][1,3,2]dioxaphosphepin BASF SE (DE) 2014-09-23 US disclosed
WO-2013098371-A1 METHOD FOR PRODUCING 6-CHLORODIBENZO [D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2013-07-04 WO disclosed
US-20130172596-A1 PROCESS FOR PREPARING 6-CHLORODIBENZO[D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2013-07-04 US disclosed
US-5910600-A Bisphosphite compound, process for its production and hydroformylation process employing the bisphosphite compound MITSUBISHI CHEMICAL CORPORATION (JP) 1999-06-08 US disclosed
EP-0509740-B1 Heat-developable photosensitive material and image forming method making use of the heat-developable photosensitive material CANON KK (JP) 1996-06-26 EP disclosed
US-5262295-A Biphenyldihydroxide reducing agent for silver halide emulsion layers CANON KABUSHIKI KAISHA (JP) 1993-11-16 US disclosed
EP-0509740-A1 Heat-developable photosensitive material and image forming method making use of the heat-developable photosensitive material CANON KABUSHIKI KAISHA (JP) 1992-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172596-A1 PROCESS FOR PREPARING 6-CHLORODIBENZO[D,F][1,3,2]DIOXAPHOSPHEPIN DCPS, PLCB3, DDT CA2 826/4885CA1 535/4885PTGS1 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.